Authors:
Bangham, CRM
Hall, SE
Jeffery, KJM
Vine, AM
Witkover, A
Nowak, MA
Wodarz, D
Usuku, K
Osame, M
Citation: Crm. Bangham et al., Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I, PHI T ROY B, 354(1384), 1999, pp. 691-700
Authors:
Jeffery, KJM
Usuku, K
Hall, SE
Matsumoto, W
Taylor, GP
Procter, J
Bunce, M
Ogg, GS
Welsh, KI
Weber, JN
Lloyd, AL
Nowak, MA
Nagai, M
Kodama, D
Izumo, S
Osame, M
Bangham, CRM
Citation: Kjm. Jeffery et al., HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy, P NAS US, 96(7), 1999, pp. 3848-3853
Citation: D. Wodarz et Ma. Nowak, Specific therapy regimes could lead to long-term immunological control of HIV, P NAS US, 96(25), 1999, pp. 14464-14469
Authors:
Taylor, GP
Hall, SE
Navarrete, S
Michie, CA
Davis, R
Witkover, AD
Rossor, M
Nowak, MA
Rudge, P
Matutes, E
Bangham, CRM
Weber, JN
Citation: Gp. Taylor et al., Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy, J VIROLOGY, 73(12), 1999, pp. 10289-10295
Authors:
Ogg, GS
Jin, X
Bonhoeffer, S
Moss, P
Nowak, MA
Monard, S
Segal, JP
Cao, Y
Rowland-Jones, SL
Hurley, A
Markowitz, M
Ho, DD
McMichael, AJ
Nixon, DF
Citation: Gs. Ogg et al., Decay kinetics of human immunodeficiency virus-specific effector cytotoxicT lymphocytes after combination antiretroviral therapy, J VIROLOGY, 73(1), 1999, pp. 797-800